Literature DB >> 2458643

FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes.

V Warty1, W Diven, E Cadoff, S Todo, T Starzl, A Sanghvi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2458643      PMCID： PMC2954623          DOI： 10.1097/00007890-198809000-00025

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  9 in total

1.  Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation.

Authors:  S Sawada; G Suzuki; Y Kawase; F Takaku
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

2.  Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.

Authors:  T Ochiai; K Nakajima; M Nagata; T Suzuki; T Asano; T Uematsu; T Goto; S Hori; T Kenmochi; T Nakagoori
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

3.  Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A.

Authors:  A Zeevi; R Duquesnoy; G Eiras; H Rabinowich; S Todo; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

4.  FK-506 enhances cyclosporine uptake by peripheral blood lymphocytes.

Authors:  A Sanghvi; V Warty; A Zeevi; W Diven; R Duquesnoy; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

5.  Depletion of monocytes from human peripheral blood mononuclear leukocytes: comparison of the sephadex G-10 column method with other commonly used techniques.

Authors:  T R Jerrells; J H Dean; G L Richardson; R B Herberman
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

6.  Binding of cyclosporine by human lymphocytes and phospholipid vesicles.

Authors:  S J LeGrue; A W Friedman; B D Kahan
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

7.  IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION.

Authors:  A Zeevi; R Duquesnoy; G Eiras; S Todo; L Makowka; T Starzl
Journal:  Surg Res Commun       Date:  1987

8.  Kinetics of uptake and intracellular binding of Cyclosporine A in RAJI cells, in vitro.

Authors:  I Fabre; G Fabre; N Lena; J P Cano
Journal:  Biochem Pharmacol       Date:  1986-12-01       Impact factor: 5.858

9.  Uptake and nature of the intracellular binding of cyclosporin A in a murine thymoma cell line, BW5147.

Authors:  M P Merker; M M Merker; R E Handschumacher
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422
  9 in total
  6 in total

Review 1.  Micro and nanoparticle drug delivery systems for preventing allotransplant rejection.

Authors:  James D Fisher; Abhinav P Acharya; Steven R Little
Journal:  Clin Immunol       Date:  2015-05-01       Impact factor: 3.969

2.  Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience.

Authors:  K Abu-Elmagd; S Todo; J Fung; J Demetris; J Rakela; A S Rao; S Iwatsuki; T Starzl
Journal:  Clin Transpl       Date:  1994

Review 3.  Current status of renal transplantation.

Authors:  M G Suranyi; B M Hall
Journal:  West J Med       Date:  1990-06

4.  Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506.

Authors:  P Walliser; C R Benzie; J E Kay
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

Review 5.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

6.  Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression.

Authors:  S Todo; J J Fung; T E Starzl; A Tzakis; H Doyle; K Abu-Elmagd; A Jain; R Selby; O Bronsther; W Marsh
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.